Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Evaluation of AUP12602-C as New Topical Treatment for DFUs (DIAMEND STUDY)
Details : AUP1602-C is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetic Foot.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 01, 2023
Lead Product(s) : AUP-16
Therapeutic Area : Podiatry
Study Phase : Phase I/ Phase II
Sponsor : Xbiome
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the license and collaboration agreement, Xbiome acquires exclusive development and commercial rights for all human use to Aurealis clinical stage DFU drug candidate AUP-16 in Mainland China, Hong Kong, Macao, and Taiwan.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
January 28, 2022
Lead Product(s) : AUP-16
Therapeutic Area : Podiatry
Highest Development Status : Phase I/ Phase II
Sponsor : Xbiome
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : AUP1602-C
Therapeutic Area : Podiatry
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Diabetic Foot Ulcers With AUP1602-C
Details : AUP1602-C is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetic Foot.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 24, 2020
Lead Product(s) : AUP1602-C
Therapeutic Area : Podiatry
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
